



## Evolva selected to acquire certain Fluxome assets

Reinach, Switzerland, 21 November 2012 – Evolva Holding SA (SIX: EVE) today announces it has entered an agreement to acquire certain assets owned by Fluxome Sciences A/S, a Danish private company that is in reconstruction. The agreement is subject to creditor and court approval, which is anticipated to occur in the next two weeks. Further information will be provided if approval is obtained. The transaction is not expected to change Evolva's 2012 financial projections.

- ends -

### About Evolva

Evolva's mission is to discover and provide **innovative, sustainable ingredients for health, nutrition and wellness**. Evolva uses biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. For more information see [www.evolva.com](http://www.evolva.com).

### Contact Details

Neil Goldsmith, CEO  
[neilg@evolva.com](mailto:neilg@evolva.com)  
+ 41 61 485 2005

Jakob Dynnes Hansen, CFO  
[jakobdh@evolva.com](mailto:jakobdh@evolva.com)  
+ 41 61 485 2034

Paul Verbraeken, IR  
[paulv@evolva.com](mailto:paulv@evolva.com)  
+ 41 61 485 2035

*This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.*